Roche Palo Alto LLC

Hoffmann-La Roche Inc.

Janssen Pharmaceutica Nv

F. Hoffmann-La Roche Ag

Rama K Kondru

Yan Lou

Timothy D Owens

Michael Soth

Robert Than Hendricks

Nolan James Dewdney

Johannes Cornelius Hermann

Joel McIntosh

Bradley E Loe

Todd Richard Elworthy

Daisy Joe DuBois

David Bernard Smith

Francisco Javier Lopez-Tapia

Stephen Matthew Lynch

Hanbiao Yang

Zachary Kevin Sweeney

Christine E Brotherton-Pleiss

Calvin Wesley Yee

Remy Lemoine

Joshua Paul Gergely Taygerly

Joshua Kennedy-Smith

Joe Timothy Bamberg

Jun Morimura

Jessica Lee

Lichen Shen

Thomas Doyle

Yimin Qian

Eric Brian Sjogren

Ronald Charles Hawley

Sung-Sau So

Alam Jahangir

Roland Joseph Billedeau

Tobias Gabriel

Kshitij Chhabilbhai Thakkar

Daisy Joe Du Bois

Jutta Wanner

Yingjie Lai

Jaehyeon Park

Omar Jose Morales

Ramona Hilgenkamp

Calvin Yee

Bradley E Loc

Mark Bartlett

Francisco Javier Lopez-tapia

Disclosed embodiments facilitate healthcare system security and interoperability. In some embodiments, a first entity may receive, in response to a transaction at a first time, encrypted information blocks pertaining to the transaction from one or more second entities. Each encrypted information block may be received from a distinct second entity and may comprise at least one sub-block decryptable by the first entity. The first entity may decrypt the decryptable sub-blocks and augment a multi-dimensional blockchain. The multi-dimensional blockchain may be augmented with a multi-dimensional block formed by linking at least one of the encrypted information blocks received from the one or more second entities to a current block being added to a blockchain associated with the transaction and maintained by the first entity. The first entity may then enable access to the multi-dimensional blockchain for at least one of the one or more second entities.

System and method for healthcare security and interoperability

This application discloses compounds according to generic Formula I: (I) wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

Inhibitors of bruton's tyrosine kinase

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-IV: wherein, variables R, X, Y, Y, Y, Y, Y, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-IV and at least one carrier, diluent or excipient.

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X' and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Pyrrolopyrazine kinase inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q, R, R, and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

This application discloses 6-Phenyl-imidazo[1,2-a]pyrazine derivatives according to generic Formulae I-V: wherein, variables Q, R, Y, Y, Y, Y, n, and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-V and at least one carrier, diluent or excipient.

Inhibitors of Bruton's tyrosine kinase

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and Rand Rare defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-II: wherein, variables Q, Q, R, X, Y, Y, Y, Y, Y, Y, m, and p are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-II and at least one carrier, diluent or excipient.

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q, R, and X are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Growing community of inventors

Sunnyvale, CA, United States of America

Rama K Kondru